10 INTANGIBLE ASSETS AND GOODWILL (CONTINUED) SubB2M - which is in the research phase and therefore pre-revenue, was assessed for impairment using the fair value less cost of disposal methodology (determined with reference to replacement cost method due to inability to reliably estimate future cash flows as the technology is still undergoing development). The cost approach reflects the amount that would be required currently to replace the service capacity of an asset less any wastage, obsolescence and costs of disposal. Management determined that no impairment was present at balance date. 11 RIGHT OF USE ASSETS As at 30 June 2026 $ As at 30 June 2025 $ Right-of-use Asset – at cost – 1,510,256 Accumulated depreciation – (1,387,772) – 122,484 The Group’s Head Office lease entered into by subsidiary Sienna Cancer Diagnostics Limited at 23 Normanby Rd Notting Hill expired on 6 June 2026. INOVIQ is currently on a month-to-month tenancy arrangement. Accordingly, there is no right of use asset and no lease liability at 30 June 2026. 12 TRADE AND OTHER PAYABLES As at 30 June 2026 $ As at 30 June 2025 $ Trade and other payables 275,094 346,233 Accruals 486,025 533,988 761,119 880,221 Trade and other payables are generally unsecured, interest free and with terms ranging from 7 to 30 days. 13 LEASE LIABILITY As at 30 June 2026 $ As at 30 June 2025 $ Current Lease liability – 162,253 Non-current Lease liability – – Maturity analysis Less than 12 months – 162,253 Greater than 12 months and less than 5 years – – Greater than 5 years – – – 162,253 Notes to the Financial Statements continued for the year ended 30 June 2026 50 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3